Corrigendum.
In the Case Report by Francesca Martella, Carlotta Bacci, Clara Giordano, Francesco Montagnani, Elena Gelain, Loredana Rabatti & Luisa Fioretto, titled "Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience", which appeared in the August 2015 issue of Future Oncology 11(15s), 31–36 (2015), the following sentences were presented incorrectly. Incorrect sentence on page 32: In the present retrospective analysis, eribulin was always initially infused intravenously at the standard dose of 1.4 mg/m2 for 2–5 min on days 1 and 8 every 3 weeks, until disease progression, severe toxicity or patient refusal. Incorrect sentence on page 35: In the present retrospective analysis, eribulin was always initially infused at the standard dose of 1.4 mg/m2 in 2–5 min intravenous on days 1 and 8 every 3 weeks, until disease progression, severe toxicity or patient refusal. The correct presentation of these sentences should be: Correct sentence on page 32: In the present retrospective analysis, eribulin was always initially infused intravenously at the standard dose of 1.23 mg/m2 for 2–5 min on days 1 and 8 every 3 weeks, until disease progression, severe toxicity or patient refusal. Correct sentence on page 35: In the present retrospective analysis, eribulin was always initially infused at the standard dose of 1.23 mg/m2 in 2–5 min intravenous on days 1 and 8 every 3 weeks, until disease progression, severe toxicity or patient refusal. The authors and editors would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.